becoming more enlightened, and in this life of continuos, learning cycle....
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Receives Patent in Australia for Its Novel Monotherapeutic Compounds to Treat CNS and PNS Disorders
9:00 am ET March 19, 2020 (PR Newswire) Print
Medical Marijuana, Inc. (OTC: MJNA) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its portfolio investment company Kannalife, Inc. ("Kannalife") (OTCQB: KLFE) has been issued Australian Patent AU2015204609B2 (the "Patent") specific to "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy." With this Patent, Kannalife now holds seven patents across the globe.
"Medical Marijuana, Inc. and our portfolio of companies such as Kannalife are committed to widening knowledge and acceptance of cannabis and cannabinoid-related studies around the world," said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. "Kannalife is pushing forward that goal with new patents in six countries."
KLS-13019 leads Kannalife's intellectual property estate of novel, monotherapeutic molecules ("KLS Family"), which are capable of acting as neuroprotective agents and have the potential to treat a range of diseases, including nervous system, oxidative stress, and neurodegenerative disorders.
"With this Patent, we are honored that so many jurisdictions have recognized our IP estate as novel and proprietary," said Dean Petkanas, CEO of Kannalife. "We see this as an important step towards commercializing our lead drug candidate KLS-13019 in several markets in the future, including the Australian pharmaceutical market, which is expected to reach $32.1 billion in 2020 alone."
Of the seven patents issued to Kannalife on this technology, two are U.S. patents and five are foreign patents claiming priority to Kannalife's original 2014 U.S. filing date through international application PCT/US2015/010827, which was published as WO2015/106108A2 titled, "Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy" (the "PCT Patent").
Additionally, Kannalife has national phase patent applications based on the PCT Patent application pending in Canada, Brazil and India.
About KLS-13019KLS-13019 is Kannalife's leading proprietary, investigational, novel, monotherapeutic product for the potential treatment of a range of neurodegenerative and neuropathic pain disorders, beginning with chemotherapy-induced peripheral neuropathy (CIPN). KLS-13019 has not been reviewed or approved for patient use by the U.S. Food and Drug Administration (FDA) or any other healthcare authority in the world. It's safety and efficacy have not been confirmed by FDA-approved research.
About Kannalife, Inc.Kannalife, Inc. is a biopharmaceutical med-chem company focused on the development of proprietary and patented novel monotherapeutic molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE), a disease associated with highly repetitive impact injuries in professional and amateur sports.
The Company's KLS Family of proprietary molecules focuses on treating oxidative stress-related diseases such as HE, chronic pain from neuropathies like CIPN, and neurodegenerative diseases like CTE. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.
For more information about Kannalife, Inc., visit www.kannalife.com and visit the Company's Twitter page at @Kannalife.
About Medical Marijuana, Inc.We are a company of firsts(R). Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway(R) and HempMeds(R); a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its pharmaceutical investment companies and partners including AXIM(R) Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. The company's flagship product Real Scientific Hemp Oil has been used in several successful clinical studies throughout Mexico and Brazil to understand its safety and efficacy.
Medical Marijuana, Inc.'s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com. To see Medical Marijuana, Inc.'s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.'s shop.
FORWARD-LOOKING DISCLAIMERThis press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSUREThese statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
LEGAL DISCLOSUREMedical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
nope its not a BK company- has large revenue-being the only importer to RUSSIA is very substantial.
I did until last week- this is bottom feeder level and indeed is most likely a double -tripple at least when an audit comes out. They hired the right people and said in first part of 2020 they would have audited financials. hitting heavy and waiting... this company is priced at BK or startup which its not.. share structure large which is good for trading down the road. Not trading it now but just loading. having 2 million shares here is so cheap..
Mar 03, 2020 (Stock Market Press via COMTEX) -- CBD may not in itself offer a cure for the devastating coronavirus in humans, but it may play a larger role in treating canine coronavirus, experts say. The interplay between coronavirus in animals -- such as fowl, dogs, pigs and cows -- and humans is still being studied and may have played a role in the current global spread of the disease. CBD is not a cure for coronavirus in humans although it has properties that address key elements. CBD is known to offer anti-viral, anti-inflammatory and anti-bacterial properties. It also acts as an effective treatment for nausea and vomiting, which can be induced by the coronavirus in humans.
The impact of the coronavirus globally has also intensified coverage of CBD. Companies such as stockmarketpress.com features coverage of CBD related stocks such as CBD Unlimited, Inc. (OTC PINK: EDXC), Canopy Growth Corp. (NYSE: CGC), New Age Beverages Corp. (NASDAQ: NBEV), GW Pharmaceuticals PLC (NASDAQ: GWPH), Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT). Aurora Cannabis Inc. (NYSE:ACB) (TSX: ACB), Supreme Cannabis Co. (OTC:SPRWF) and OrganiGram Holdings Inc. (NASDAQ: OGI).
CBD May Not Be A Cure For Coronavirus In Humans, But May Play A Larger Role In Treating Canine Coronavirus
In animals, the canine coronavirus is an intestinal infection which can be transmitted by exposure to the feces of an infected dog. according to the site thoughtcloud.net. Overcrowding and unsanitary conditions can also be factors in its transmission, experts report. CBD may not be a cure for coronavirus in humans, but may play a larger role in treating canine coronavirus.
CBD's Role In Fighting Canine Coronavirus
CBD can help fight canine coronavirus, due to its anti-inflammatory and antiemetic properties. CBD oil also has antiviral properties making it a potent cannabinoid to fight the virus. CBD can also fight the feeling of nausea in dogs suffering from canine coronavirus. A veterinarian may prescribe antibiotics, too. CBD may not be a cure for coronavirus in humans, but may play a larger role in treating canine coronavirus. It is painkilling, antiviral, anti-nausea and strengthens the immune systems of dogs.https://www.marketwatch.com/press-release/cbd-may-not-be-a-cure-for-coronavirus-in-humans-but-may-play-a-larger-role-in-treating-canine-coronavirus-2020-03-03
Cannabis shops take preventive measures in response to coronavirus, report fewer customers yet larger purchaseshttps://mjbizdaily.com/cannabis-shops-take-preventive-measures-in-response-to-coronavirus-report-fewer-customers-yet-larger-purchases/
MEDICAL MARIJUANA, INC. APPOINTS SQUAR MILNER LLP AS NEW INDEPENDENT AUDITOR- SAN DIEGO, Feb. 18, 2020 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), announced today that it has appointed Squar Milner LLP (“Squar Milner”) as the Company’s new independent registered public accounting firm. Squar Milner will begin work immediately on the audit of Medical Marijuana, Inc.’s December 31, 2019 consolidated balance sheet.
“After a thorough selection process, we are delighted to welcome Squar Milner as our independent auditor. The firm’s experience auditing companies that that are publicly listed in the U.S. offers us a wealth of talent, expertise and resources,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “We look forward to seeing our 2019 audit that Squar Milner is currently working on and plan to maintain a long-term relationship with them.”
Squar Milner is one of the nation’s top 50 largest accounting firms, as well as one of the largest independent accounting and advisory firms in California. They provide audit, tax and consulting services and have been registered by the Public Company Accounting Oversight Board since 2003. Squar Milner is led by a partner group of experienced professionals who are experts in providing audit and assurance services to publicly held and privately held clients and have extensive experience providing management and business advisory services.
“We are proud to have retained one of the top audit firms in the country. Squar Milner will help us to improve our public reporting practices and increase transparency to shareholders,” said Medical Marijuana, Inc. Chief Financial Officer Brooke Beers.”
About Squar Milner LLP
Squar Milner is a leading provider of accounting and financial advisory services to clients across the United States. Squar Milner is an independent member of an association of over 100 independent accounting and consulting firms with offices in more than 70 countries that are selected on the basis of reputation, clientele, performance and professionalism.
About Medical Marijuana, Inc.
We are a company of firsts®. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space: a global portfolio of cannabinoid-based nutraceutical brands led by Kannaway® and HempMeds®; a pioneer in sourcing the highest-quality legal non-psychoactive cannabis products derived from industrial hemp; and a cannabinoid-based clinical research and botanical drug development sector led by its internal R&D and scientific team and its pharmaceutical investment companies and partners including AXIM® Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD producer by CNBC. Medical Marijuana, Inc. was also the first company to receive historic import permits for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the development of international markets. Medical Marijuana, Inc.’s headquarters is in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com.
To see Medical Marijuana, Inc.’s corporate video, click here.
Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.
CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
andrew.hard@cmwmedia.com
www.cmwmedia.com
We are working daily to put the appropriate procedures in place to meet the standards and transparency required of a NASDAQ listed company. We pledge that transparency will be a major focus for us moving forward. We hope to be fully GAAP-compliant with audited financials starting in year 2020. We continue to consult with financial experts on improving our debt position, limiting dilutive financings and improving our level of financial reporting.
I thought news was substantial today- they are venturing into The whole Russian market all by themselves
GAAP compliance explained
Being GAAP compliant essentially means that you have maintained financial records in a way that allows investors, lending institutions, prospective buyers, etc. to make a sound decision regarding your company. For the average entrepreneur or small business owner with a terrific idea or great product, GAAP will not even be on the radar. As soon as you need some financing for expansion or are approached by a potential buyer, however, you will need to be compliant.
WOW- no traders here, that's very good- this can now slowly sneak up under the radar. By the price of Other Big Bird listed MJ stocks compared to MJNA and what they have achieved and are currently doing gives reasoning that even with the big share structure this should be at least .07 cents a share when the audited financial come out April 16th. We know officially know that an audit will be transpiring because of who they hired and what they are currently doing. I feel they want to be a higher exchange. This could easily be a ten bagger from this level and that's not far off from examining all the logistics. They are now the only CBD company that will be exporting to RUSSIA. The news will slowly take effect because it a ginormous achievement.
Seems this was actually for once safest place to put money seeing the Price Per SHARE. We kn ow with the companies under their belt and how long they have been in this industry tells me they have some plans. The price is factored in as either a bankrupt company- no viable business and a totally scam. So hare dumping over the years may have help indicate this but in some due diligence on what is currently up their sleeve should get people to start to notice this stock once again. The Kannaway DNA kit I feel is simply awesome. So seeing how I lost 50% of my current portfolio because of the situation and fear in general. So I place some of it here as a side project so I don't have to look at this dreadful market. So I am placing my money where my mouth is and purchased 1.4 million shares last two trading sessions. I may even get more because this seems like a lifetime opportunity all over once again. People are not around this stock anymore because of the above so like myself they have missed all the good news that has been in fruition. The AUDIT alone was one of the top two complaints on this stock and was so easy to say so or trash the stock because they didn't care to audit themselves and act professional like they mean it. I feel they do at this point and they have to. I mean look at the dismal price. But a lifetime opportunity for a triple bagger because of the audit which we are now told will be 4/16/2020.
Nice close....
$GSAT earnings announcement on Thursday- gut instinct says earnings beats the street and forward looking statement on Nokia partnership and spectrum value should be and can be remarkable.
Nyse News Times- M2M Satellite Communication Market Research 2020: Key Players- Orbcomm, Inmarsat Communications, Iridium Communications, Globalstar- https://nysenewstimes.com/m2m-satellite-communication-market-research-2020-key-players-orbcomm-inmarsat-communications-iridium-communications-globalstar/
NEWS- Phone Market by 2020-2027 Major Players Profiling Iridium, Globalstar, BYOD Devices, Inmarsat https://galusaustralis.com/2020/02/481008/huge-demand-for-mobile-satellite-phone-market-by-2020-2027-major-players-profiling-iridium-globalstar-byod-devices-inmarsat/
PHUCKING MOVE G DANGIT..... MANIPULATION IS SO UNBELIEVABLE HERE... IT IS AS OBVIOUS AS THE SUN SHINNING. EVERYONE CAN SEE IT AND EVERYONE SEES THE INSIDERS THAT LIE TO GET CHEAPER SHARES.
may become a bidding feud for spectrum.. https://thefly.com/landingPageNews.php?id=3032081&headline=I;VZ;TMUS;S-Verizon-may-turn-attention-to-Intelsat-after-TMobile-nod-Dealreporter-says
not a good view at close of day with 10% down.. this has started a descension and is acting like the market knows some bad news is coming.... I got out with a 4,600 dollar loss for this trade. I would be watching out for a major selloff at this point... keep a good eye on her... good luck everyone
Hey- these guys INTELSAT prolly getting 7 to 8 billion total which is monumental and payout could be more as this is a minimum price as a default. means they are here to stay and rise above....
BULL AND BEARS- This has calmed down and back in because its going back to test recent highs. it is totally a given and once we get that MACD cross its game on old friends...
good news here"Net income attributable to common shareholders for the fourth quarter 2019 was $46.5 million, or $0.27 per diluted share, compared with a net loss of $65.5 million, or a loss of $0.38 per diluted share, for the fourth quarter of 2018. Net income for the fourth quarter 2019 was impacted by a $37.4 million loss on impairment of real estate to write down the carrying value of Park Plaza to the property’s estimated fair value.
poison stock at this point- BK happening within a mon th as the bleeding continues...... t
WARNING-Intelsat Said to Weigh Chapter 11 Among Options on C-Band Plan- ntelsat SA is considering a possible Chapter 11 bankruptcy filing if U.S. regulators don’t increase the amount of compensation the company would receive for giving up some of its airwaves, a person close to the company said.
Intelsat has hired bankruptcy experts at Kirkland & Ellis LLP to prepare for possible restructuring, said the person who spoke on condition of anonymity because the matter isn’t public.
https://news.bloomberglaw.com/tech-and-telecom-law/intelsat-said-to-weigh-chapter-11-among-options-on-c-band-plan
I wouldn't even touch this at this point..... bond holders want 5g payout through bankruptcy because then shareholders get wiped out- after reorganization it will be a buy or when they get the Q. way too risky now after the several halts- why no halt on its way down from 11 dollars or even 6 dollars..
Got out at 4.115. and then 3.905.. wow look what happened I feel blessed and sorry for others taking this huge hit. Who knew? Well insiders knew........ us little peeps just gamble. win some and lose some but hopefully to trade another day....
congrats...
I like your post very much so.... Intelsat to test next resistance and support which is SIX BUCKS!!! 6 DOLLARS, $6.00 ... that's six dollars
I see the future.... has it played out for you? I hope so...
well the 3 dollar test support obviously was in no way going to happen in an ascension and cover currently in the works..... but I wasn't gonna say anything at the time but just chuckled. not even gonna watch it I just draw lines on Ameritrade to see the channels for trading sequences. you have been around these part almost as long as myself. so I do say good luck and cheers...
THIS STOCK IS POISON- STAY AWAY
move and get offf the chit pot slow poke have some news like a real company. chart setting up so lets get with it its like watching paint dry. simple to have news. act real enough and they come no questions asked
I SMELL NEWS.... who else does.... something is up and ascension seems to be the word right now... happens when something is about to transpire and market knows
29 million short cover over next few days....float is still tiny with insiders still holding it appears
I tend to agree and bought some shares to have and to hold
that's some heavy hitters reinforcing fairness unto the blinded aspects of the FCC who seem to be horrible at fair communications which is highly odd but accurate of their stance. I don't think they want this to be dragged out for years as the government would go broke and lose its power house status as they set themselves on the back burners of logistics slowing down America as the power house its critical data. in simple terms their current stance is completely ridiculous.
GOOD NEWS FOR STOCK PRICE: "A practical concern with the public auction is that the FCC's actions may unleash a flurry of lawsuits by the satellite companies that could delay the deployment of this vital resource -- thus defeating the speedy-resolution purpose of the public auction in the first place. A group representing the current owners of this spectrum, the C-Band Alliance, told The Wall Street Journal that the government-run auction is bound to be delayed by "protracted litigation" that could take two to four years."
its not a doom and gloom its actually a reality- I have been through these before and if you look at when my alias was created it was 2003, so I have a track record and even pending lawsuits are not good for market perception. good luc
more lawsuits- I sold out this is gonna dive more- leads to more bad news when a plaintiff comes into these lawsuits which they will and I don't want to be around...
CTST looking prime today fora starter